Iovance Biotherapeutics, Inc. filings document a biotechnology company focused on polyclonal TIL therapies, including disclosures tied to Amtagvi, Proleukin, lifileucel, and broader solid-tumor cell therapy programs. Its Form 8-K reports cover operating results, financial condition, corporate presentations, clinical or regulatory disclosures, and material-event updates.
The filing record also includes proxy materials covering director elections, executive compensation, shareholder voting matters, and board governance. Capital-structure disclosures include common stock matters, registration-statement references, and material agreements related to an at-the-market offering program.
Iovance Biotherapeutics, Inc. proposes to offer up to $89,650,167 of common stock via an at-the-market program through Jefferies.
The prospectus supplement states sales may total up to 22,811,747 shares assuming an offering price of $3.93 per share and reports 438,106,537 shares outstanding as of March 31, 2026, rising to up to 460,918,284 shares outstanding after this offering if fully sold. Proceeds are designated to support the commercial launch of Amtagvi®, clinical programs including IOV-LUN-202 and TILVANCE-301, pipeline development and general corporate purposes.
Iovance Biotherapeutics reported that stockholders approved all seven proposals at its Annual Meeting, including an amendment to the 2020 Employee Stock Purchase Plan adding 1,000,000 shares and an increase in authorized common stock from 500,000,000 to 650,000,000 shares. Directors were re-elected, executive compensation received advisory approval, and Ernst & Young LLP was ratified as auditor.
The company also received marketing authorization from Australia’s Therapeutic Goods Administration for Amtagvi (lifileucel) to treat previously treated advanced melanoma. Amtagvi is described as the first T cell therapy for a solid tumor cancer and the first option in Australia for advanced melanoma after anti-PD-1 and targeted therapy.
IOVANCE BIOTHERAPEUTICS Interim CEO & General Counsel Frederick G. Vogt reported routine equity compensation activity involving restricted stock units (RSUs). On 2026-06-05, RSUs vested and were converted into 15,625 shares of common stock at a stated price of $0.00 per share.
To cover mandatory tax withholding on this vesting, 6,638 shares of common stock were withheld at $4.23 per share. After these transactions, Vogt directly held 562,492 shares of common stock and 109,382 RSUs, with each RSU representing a contingent right to receive one share and the remaining RSUs scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Medical Officer Friedrich Graf Finckenstein reported routine equity compensation activity involving restricted stock units (RSUs). On the transaction date, 7,813 RSUs vested, each converting into one share of common stock. These shares were acquired through an option-style derivative exercise at a stated price of $0.00 per share.
To cover mandatory tax withholding on the vesting, 3,976 common shares were withheld by the company, which the filing clarifies was not an open market sale. After these transactions, the officer directly held 140,111 shares of common stock. The filing also notes 54,691 RSUs remaining from a March 5, 2025 grant, which will vest in equal quarterly installments, providing additional potential future share deliveries as they vest.
IOVANCE BIOTHERAPEUTICS, INC. reports that Chief Regulatory Officer Raj K. Puri had 9,766 restricted stock units vest on June 5, 2026, converting into an equal number of common shares at a $0.00 exercise price.
To satisfy mandatory tax withholding, 3,843 of the newly issued shares were withheld by the company at $4.23 per share; this was not an open-market sale. After these transactions, Puri directly holds 248,114 shares of common stock. RSUs from the same grant are scheduled to continue vesting in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Operating Officer Igor Bilinsky reported routine equity compensation activity. On the transaction date, 7,813 restricted stock units (RSUs) vested into shares of common stock, each RSU representing a right to receive one share. To cover mandatory tax withholding on this vesting, 3,976 shares of common stock were withheld by the company; this was explicitly not an open market sale. After these events, Bilinsky directly holds 133,920 shares of common stock and 54,691 RSUs from a March 5, 2025 grant, which are scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS Interim CEO & General Counsel Frederick G. Vogt had restricted stock units vest into 41,668 shares of common stock on the transaction date. The company withheld 17,701 shares to cover mandatory tax obligations, which was not an open-market sale. Following these transactions, Vogt directly held 553,505 common shares and 125,007 remaining RSUs that will vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS Chief Regulatory Officer Raj K. Puri reported routine equity compensation activity. On June 1, 2026, 5,469 restricted stock units (RSUs) vested and converted into the same number of common shares. Of these, 2,508 shares were withheld by the company to cover mandatory tax obligations, which the filing specifies was not an open-market sale. After these transactions, Puri directly holds 242,191 shares of common stock and 16,409 RSUs from the referenced grant, which will continue to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS, INC. Chief Medical Officer Friedrich Graf Finckenstein reported routine equity compensation activity involving restricted stock units (RSUs) and related tax withholding. On the transaction date, RSUs covering 8,790 shares of common stock vested, and an equivalent number of common shares were issued upon conversion of the RSUs.
To cover mandatory tax withholding on this vesting, 4,473 common shares were withheld by the company at a price of $3.96 per share, which the filing notes was not an open market sale. After these transactions, the reporting person directly held 136,274 shares of common stock and 26,369 RSUs, with the remaining RSUs scheduled to vest in equal quarterly installments.
IOVANCE BIOTHERAPEUTICS Chief Operating Officer Igor Bilinsky reported routine equity compensation activity. On the transaction date, 8,790 restricted stock units (RSUs) vested into an equal number of common shares. The company withheld 4,473 shares at $3.96 per share to cover mandatory tax obligations, which was not an open-market sale. Following these transactions, Bilinsky directly held 130,083 shares of common stock and 26,369 RSUs that will continue to vest in equal quarterly installments.